Comparative Pharmacology
Head-to-head clinical analysis: ANTRENYL versus HICON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTRENYL versus HICON.
ANTRENYL vs HICON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antrenyl (oxyphenonium bromide) is a quaternary ammonium anticholinergic agent that competitively blocks acetylcholine at muscarinic receptors in smooth muscle, exocrine glands, and the CNS, leading to reduced gastrointestinal motility and secretion.
Unknown; possibly involves modulation of hypothalamic thermoregulatory center.
50 mg orally 3 times daily initially, then adjust to 50-100 mg 3 times daily; 20 mg intramuscularly or intravenously every 4-6 hours as needed.
HICON (norepinephrine) 0.05-0.5 mcg/kg/min IV continuous infusion, titrated to blood pressure.
None Documented
None Documented
2-4 hours (terminal), requiring q6-8h dosing for sustained anticholinergic effect
Terminal half-life: 12-18 hours; prolonged to 24-36 hours in renal impairment (CrCl <30 mL/min)
Renal (80% as unchanged drug and metabolites), biliary/fecal (20%)
Renal: 70% as unchanged drug; biliary/fecal: 25% as metabolites; 5% other
Category C
Category C
Anticholinergic
Anticholinergic